-
1
-
-
10944255947
-
Focus on myeloproliferative diseases and myelodysplastic syndromes
-
Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004;6:547-52
-
(2004)
Cancer Cell
, vol.6
, pp. 547-552
-
-
Van Etten, R.A.1
Shannon, K.M.2
-
2
-
-
77956534350
-
Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO)
-
Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S, Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Tyrosine kinase inhibitors. Curr Cancer Drug Targets 2010;10: 462-83
-
(2010)
Curr Cancer Drug Targets
, vol.10
, pp. 462-483
-
-
Natoli, C.1
Perrucci, B.2
Perrotti, F.3
Falchi, L.4
Iacobelli, S.5
-
3
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, B.J.1
-
4
-
-
34249676964
-
Chronic myeloid leukaemia as a model of disease evolution in human cancer
-
Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 441-453
-
-
Melo, J.V.1
Barnes, D.J.2
-
6
-
-
84881298446
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
-
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122:872-84
-
(2013)
Blood
, vol.122
, pp. 872-884
-
-
Baccarani, M.1
Deininger, M.W.2
Rosti, G.3
Hochhaus, A.4
Soverini, S.5
Apperley, J.F.6
-
8
-
-
77949767505
-
International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatini
-
(abstr 1126)
-
Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:462 (abstr 1126)
-
(2009)
Blood
, vol.114
, pp. 462
-
-
Deininger, M.1
O'Brien, S.G.2
Guilhot, F.3
Goldman, J.M.4
Hochhaus, A.5
Hughes, T.P.6
-
9
-
-
84863011486
-
Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
-
Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
-
(2012)
Blood
, vol.119
, pp. 1123-1129
-
-
Kantarjian, H.M.1
Shah, N.P.2
Cortes, J.E.3
Baccarani, M.4
Agarwal, M.B.5
Undurraga, M.S.6
-
10
-
-
84867395848
-
Nilotinib vs. Imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
-
Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs. imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
-
(2012)
Leukemia
, vol.26
, pp. 2197-2203
-
-
Larson, R.A.1
Hochhaus, A.2
Hughes, T.P.3
Clark, R.E.4
Etienne, G.5
Kim, D.W.6
-
11
-
-
84867405606
-
Standardized definitions of molecular response in chronic myeloid leukemia
-
Cross NCP, White H,M Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172-5
-
(2012)
Leukemia
, vol.26
, pp. 2172-2175
-
-
Cross, N.C.P.1
White, H.M.2
Muller, M.C.3
Saglio, G.4
Hochhaus, A.5
-
12
-
-
84859871645
-
Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques
-
Tibes R, Mesa RA. Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. Leuk Res 2012;36:664-71
-
(2012)
Leuk Res
, vol.36
, pp. 664-671
-
-
Tibes, R.1
Mesa, R.A.2
-
13
-
-
79952381341
-
Monitoring molecular response in chronic myeloid leukemia
-
Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 2011;117:1113-22
-
(2011)
Cancer
, vol.117
, pp. 1113-1122
-
-
Cortes, J.1
Quintas-Cardama, A.2
Kantarjian, H.M.3
-
14
-
-
33745603988
-
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
-
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37
-
(2006)
Blood
, vol.108
, pp. 28-37
-
-
Hughes, T.1
Deininger, M.2
Hochhaus, A.3
Branford, S.4
Radich, J.5
Kaeda, J.6
-
15
-
-
10744229080
-
Frequency of major molecular responses to imatinib or interferona plus cytarabine in newly diagnosed chronic myeloid leukemia
-
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferona plus cytarabine in newly diagnosed chronic myeloid leukemia.N Engl J Med 2003;349:1423-32
-
(2003)
N Engl J Med
, vol.349
, pp. 1423-1432
-
-
Hughes, T.P.1
Kaeda, J.2
Branford, S.3
Rudzki, Z.4
Hochhaus, A.5
Hensley, M.L.6
-
16
-
-
33744463354
-
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
-
Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-6
-
(2006)
Blood
, vol.107
, pp. 4250-4256
-
-
Press, R.D.1
Love, Z.2
Tronnes, A.A.3
Yang, R.4
Tran, T.5
Mongoue-Tchokote, S.6
-
17
-
-
20944442975
-
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
-
Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3425-3432
-
-
Cortes, J.1
Talpaz, M.2
O'Brien, S.3
Jones, D.4
Luthra, R.5
Shan, J.6
-
18
-
-
80053355373
-
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: Does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay
-
Pavlovsky C, Giere I, Moiraghi B, Pavlovsky MA, Aranguren PN, Garcia J, et al. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay. Clin Lymphoma Myeloma Leuk 2011;11:280-5
-
(2011)
Clin Lymphoma Myeloma Leuk
, vol.11
, pp. 280-285
-
-
Pavlovsky, C.1
Giere, I.2
Moiraghi, B.3
Pavlovsky, M.A.4
Aranguren, P.N.5
Garcia, J.6
-
19
-
-
77958595179
-
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon Versus STI571 (IRIS)
-
Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon Versus STI571 (IRIS). Blood 2010;116:3758-65
-
(2010)
Blood
, vol.116
, pp. 3758-3765
-
-
Hughes, T.P.1
Hochhaus, A.2
Branford, S.3
Muller, M.C.4
Kaeda, J.S.5
Foroni, L.6
-
20
-
-
79960165168
-
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era
-
Breccia M, Alimena G. The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Crit Rev Oncol Hematol 2011;79:135-43
-
(2011)
Crit Rev Oncol Hematol
, vol.79
, pp. 135-143
-
-
Breccia, M.1
Alimena, G.2
-
21
-
-
84879381539
-
Is going for cure in chronic myeloid leukemia possible and justifiable?
-
Mahon FX. Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012; 2012:122-8
-
(2012)
Hematology Am Soc Hematol Educ Program
, vol.2012
, pp. 122-128
-
-
Mahon, F.X.1
-
22
-
-
84860839007
-
Curing chronic myeloid leukemia
-
Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX. Curing chronic myeloid leukemia. Curr Hematol Malig Rep 2012;7:103-8
-
(2012)
Curr Hematol Malig Rep
, vol.7
, pp. 103-108
-
-
Rea, D.1
Rousselot, P.2
Guilhot, J.3
Guilhot, F.4
Mahon, F.X.5
-
23
-
-
54049139246
-
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
-
Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-8
-
(2008)
Blood
, vol.112
, pp. 3330-3338
-
-
Branford, S.1
Fletcher, L.2
Cross, N.C.3
Muller, M.C.4
Hochhaus, A.5
Kim, D.W.6
-
24
-
-
37249016890
-
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
-
Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080-5
-
(2007)
Clin Cancer Res
, vol.13
, pp. 7080-7085
-
-
Branford, S.1
Seymour, J.F.2
Grigg, A.3
Arthur, C.4
Rudzki, Z.5
Lynch, K.6
-
25
-
-
39049083317
-
A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts
-
Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 2008;32:579-85
-
(2008)
Leuk Res
, vol.32
, pp. 579-585
-
-
Burmeister, T.1
Reinhardt, R.2
-
26
-
-
78650625238
-
Imatinib plus peginterferon a-2a in chronic myeloid leukemia
-
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon a-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21
-
(2010)
N Engl J Med
, vol.363
, pp. 2511-2521
-
-
Preudhomme, C.1
Guilhot, J.2
Nicolini, F.E.3
Guerci-Bresler, A.4
Rigal-Huguet, F.5
Maloisel, F.6
-
27
-
-
79955018499
-
Tolerability-adapted imatinib 800 mg/d versus 400 mg/ d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia
-
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/ d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42
-
(2011)
J Clin Oncol
, vol.29
, pp. 1634-1642
-
-
Hehlmann, R.1
Lauseker, M.2
Jung-Munkwitz, S.3
Leitner, A.4
Muller, M.C.5
Pletsch, N.6
-
28
-
-
39049161669
-
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: Need for new response definitions?
-
Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008;112:837-45
-
(2008)
Cancer
, vol.112
, pp. 837-845
-
-
Kantarjian, H.1
O'Brien, S.2
Shan, J.3
Huang, X.4
Garcia-Manero, G.5
Faderl, S.6
-
29
-
-
77956263599
-
Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): A target worth aiming and achieving?
-
(abstr 505)
-
Verma D, Kantarjian HM, Shan J, O'Brien S, Verma A, Jabbour E, et al. Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): A target worth aiming and achieving? Blood 2009;114 (abstr 505)
-
(2009)
Blood
, pp. 114
-
-
Verma, D.1
Kantarjian, H.M.2
Shan, J.3
O'Brien, S.4
Verma, A.5
Jabbour, E.6
-
30
-
-
84882764248
-
Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on imatinib frontline therapy
-
(abstr 3754)
-
Etienne G, Nicolini FE, Dulucq S, Schmitt A, Hayette S, Lippert E, et al. Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on imatinib frontline therapy. Blood 2012;120 (abstr 3754)
-
(2012)
Blood
, pp. 120
-
-
Etienne, G.1
Nicolini, F.E.2
Dulucq, S.3
Schmitt, A.4
Hayette, S.5
Lippert, E.6
-
31
-
-
84883753798
-
Clinical significance of deeper molecular responses with four modalities of tyrosine kinase inhibitors as frontline therapy for chronic myeloid leukemia
-
(abstr 164)
-
Falchi L, Kantarjian HM, Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, et al. Clinical significance of deeper molecular responses with four modalities of tyrosine kinase inhibitors as frontline therapy for chronic myeloid leukemia. Blood 2012;120 (abstr 164)
-
(2012)
Blood
, pp. 120
-
-
Falchi, L.1
Kantarjian, H.M.2
Quintas-Cardama, A.3
O'Brien, S.4
Jabbour, E.J.5
Ravandi, F.6
-
32
-
-
84892692755
-
Complete molecular remission (CMR 4.5) of CML is induced faster by dose-optimized imatinib predicts better survival-results from the randomized CML-study IV
-
(abstr 67)
-
Hehlmann R, Lauseker M, Hanfstein B,M MullerMC, Schreiber A, Proetel U, et al. Complete molecular remission (CMR 4.5) of CML is induced faster by dose-optimized imatinib predicts better survival-results from the randomized CML-study IV. Blood 2012;120 (abstr 67)
-
(2012)
Blood
, pp. 120
-
-
Hehlmann, R.1
Lauseker, M.2
Hanfstein, B.M.3
Muller, M.C.4
Schreiber, A.5
Proetel, U.6
-
33
-
-
84883816690
-
Switching to nilotinib is associated with continued deeper molecular responses in CML-CP patients with minimal residual disease after≥2 years on imatinib: ENESTcmr 2-year follow-up results
-
(abstr 694)
-
Hughes TP, Lipton JH, Spector N, Leher B, Pasquini R, Clementino N, et al. Switching to nilotinib is associated with continued deeper molecular responses in CML-CP patients with minimal residual disease after≥2 years on imatinib: ENESTcmr 2-year follow-up results. Blood 2012;120 (abstr 694)
-
(2012)
Blood
, pp. 120
-
-
Hughes, T.P.1
Lipton, J.H.2
Spector, N.3
Leher, B.4
Pasquini, R.5
Clementino, N.6
-
34
-
-
4644341516
-
Discontinuation of imatinib therapy after achieving a molecular response
-
Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-5
-
(2004)
Blood
, vol.104
, pp. 2204-2205
-
-
Cortes, J.1
O'Brien, S.2
Kantarjian, H.3
-
35
-
-
1342343034
-
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
-
Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28(suppl 1):S71-3
-
(2004)
Leuk Res
, vol.28
, Issue.SUPPL. 1
-
-
Mauro, M.J.1
Druker, B.J.2
Maziarz, R.T.3
-
36
-
-
22544459376
-
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
-
Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979-81
-
(2005)
Haematologica
, vol.90
, pp. 979-981
-
-
Merante, S.1
Orlandi, E.2
Bernasconi, P.3
Calatroni, S.4
Boni, M.5
Lazzarino, M.6
-
37
-
-
21744462100
-
Dynamics of chronic myeloid leukaemia
-
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435: 1267-70
-
(2005)
Nature
, vol.435
, pp. 1267-1270
-
-
Michor, F.1
Hughes, T.P.2
Iwasa, Y.3
Branford, S.4
Shah, N.P.5
Sawyers, C.L.6
-
38
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60
-
(2007)
Blood
, vol.109
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
Legros, L.4
Cayuela, J.M.5
Maarek, O.6
-
39
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: The prospective, multicentre stop imatinib (STIM) trial
-
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: The prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
40
-
-
84860834532
-
Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Update results of the STIM study
-
(abstr 603)
-
Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood 2011;118 (abstr 603)
-
(2011)
Blood
, pp. 118
-
-
Mahon, F.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.E.6
-
41
-
-
84873483970
-
Loss of major molecular response is accurate for restarting imatinib after imatinib discontinuation in CP-CML patients with long lasting CMR: Importance of fluctuating values of MRD and interferon
-
(abstr 194)
-
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini F, Varet B, et al. Loss of major molecular response is accurate for restarting imatinib after imatinib discontinuation in CP-CML patients with long lasting CMR: importance of fluctuating values of MRD and interferon. Haematologica 2012;97(s1):77 (abstr 194)
-
(2012)
Haematologica
, vol.97
, Issue.1
, pp. 77
-
-
Rousselot, P.1
Charbonnier, A.2
Cony-Makhoul, P.3
Agape, P.4
Nicolini, F.5
Varet, B.6
-
42
-
-
84886781746
-
Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts
-
(abstr 916)
-
Rea D, Rousselot P, Guilhot F, Tulliez M, Nicolini FE, Guerci-Bresler A, et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood 2012;120 (abstr 916)
-
(2012)
Blood
, pp. 120
-
-
Rea, D.1
Rousselot, P.2
Guilhot, F.3
Tulliez, M.4
Nicolini, F.E.5
Guerci-Bresler, A.6
-
43
-
-
84864041318
-
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
-
Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012;120: 291-4
-
(2012)
Blood
, vol.120
, pp. 291-294
-
-
Marin, D.1
Hedgley, C.2
Clark, R.E.3
Apperley, J.4
Foroni, L.5
Milojkovic, D.6
-
44
-
-
84865864744
-
Early molecular and cytogenetic response is predictive for longterm progression-free and overall survival in chronic myeloid leukemia (CML)
-
Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for longterm progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102
-
(2012)
Leukemia
, vol.26
, pp. 2096-2102
-
-
Hanfstein, B.1
Muller, M.C.2
Hehlmann, R.3
Erben, P.4
Lauseker, M.5
Fabarius, A.6
-
45
-
-
67650587143
-
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
-
Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009; 113:6315-21
-
(2009)
Blood
, vol.113
, pp. 6315-21
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Jones, D.3
Shan, J.4
Borthakur, G.5
Thomas, D.6
-
46
-
-
84875876830
-
Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with CML-CP: Analysis of ENESTnd 3-year data
-
(abstr 0584)
-
Hochhaus A, Guilhot F, Haifa Al-Ali K, Rosti G, Nakaseko C, Antonio De Souza C, et al. Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with CML-CP: analysis of ENESTnd 3-year data. Haematologica 2012;97 (s1):237 (abstr 0584)
-
(2012)
Haematologica
, vol.97
, Issue.1
, pp. 237
-
-
Hochhaus, A.1
Guilhot, F.2
Haifa Al-Ali, K.3
Rosti, G.4
Nakaseko, C.5
Antonio De Souza, C.6
-
47
-
-
84892729646
-
Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up
-
(abstr 1537)
-
Hochhaus A, Boque C, Bradley Garelik MB, Manos G, Steegmann JL. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up. Haematologica 2012;97(s1):609 (abstr 1537)
-
(2012)
Haematologica
, vol.97
, Issue.1
, pp. 609
-
-
Hochhaus, A.1
Boque, C.2
Bradley Garelik, M.B.3
Manos, G.4
Steegmann, J.L.5
-
48
-
-
84857510443
-
Responses to second-line tyrosine kinase inhibitors are durable: An intention-to-treat analysis in chronic myeloid leukemia patients
-
Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012;119:1838-43
-
(2012)
Blood
, vol.119
, pp. 1838-1843
-
-
Milojkovic, D.1
Apperley, J.F.2
Gerrard, G.3
Ibrahim, A.R.4
Szydlo, R.5
Bua, M.6
-
49
-
-
79954592021
-
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system
-
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 2011;35:585-90
-
(2011)
Leuk Res
, vol.35
, pp. 585-590
-
-
Tauchi, T.1
Kizaki, M.2
Okamoto, S.3
Tanaka, H.4
Tanimoto, M.5
Inokuchi, K.6
-
50
-
-
84883636938
-
Early molecular response and female sex strongly predict achievement of stable undetectable BCR-ABL1, a criterion for imatinib discontinuation in patients with CML
-
(abstr 165)
-
Branford S, Ross D, Prime J, Field C, Altamura H, Yeoman A, et al. Early molecular response and female sex strongly predict achievement of stable undetectable BCR-ABL1, a criterion for imatinib discontinuation in patients with CML. Blood 2012;120 (abstr 165)
-
(2012)
Blood
, pp. 120
-
-
Branford, S.1
Ross, D.2
Prime, J.3
Field, C.4
Altamura, H.5
Yeoman, A.6
-
51
-
-
80052873243
-
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia
-
Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, et al. Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol 2011;93:618-23
-
(2011)
Int J Hematol
, vol.93
, pp. 618-23
-
-
Yoshida, C.1
Komeno, T.2
Hori, M.3
Kimura, T.4
Fujii, M.5
Okoshi, Y.6
-
52
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
-
(2010)
J Clin Oncol
, vol.28
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.X.3
Eliasson, L.4
Milojkovic, D.5
Bua, M.6
-
53
-
-
79953823237
-
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long term therapy
-
Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long term therapy. Blood 2011;117:3733-6
-
(2011)
Blood
, vol.117
, pp. 3733-3736
-
-
Ibrahim, A.R.1
Eliasson, L.2
Apperley, J.F.3
Milojkovic, D.4
Bua, M.5
Szydlo, R.6
-
54
-
-
84862794931
-
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
-
Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689-93
-
(2012)
Leuk Res
, vol.36
, pp. 689-693
-
-
Yhim, H.Y.1
Lee, N.R.2
Song, E.K.3
Yim, C.Y.4
Jeon, S.Y.5
Shin, S.6
-
55
-
-
84886917643
-
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
-
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013;122:515-22
-
(2013)
Blood
, vol.122
, pp. 515-522
-
-
Ross, D.M.1
Branford, S.2
Seymour, J.F.3
Schwarer, A.P.4
Arthur, C.5
Yeung, D.T.6
-
56
-
-
84892756731
-
BCR-ABL kinetics after discontinuation of imatinib in CMLpatients with MR4.5 or undetectable molecular residual disease
-
(abstr 200)
-
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Choi M, et al. BCR-ABL kinetics after discontinuation of imatinib in CMLpatients with MR4.5 or undetectable molecular residual disease. Haematologica 2012;97 (s1):80 (abstr 200)
-
(2012)
Haematologica
, vol.97
, Issue.1
, pp. 80
-
-
Lee, S.E.1
Choi, S.Y.2
Bang, J.H.3
Kim, S.H.4
Jang, E.J.5
Choi, M.6
-
57
-
-
84892773730
-
-
U.S. National Institutes of Health. Clinicaltrials.gov. [cited 2013 Sept 12]. Available from: http://www.clinicaltrials.gov/
-
U.S. National Institutes of Health. Clinicaltrials.gov. [cited 2013 Sept 12]. Available from: http://www.clinicaltrials.gov/
-
-
-
-
58
-
-
77958012952
-
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
-
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;10:1719-1724
-
(2010)
Leukemia
, vol.10
, pp. 1719-1724
-
-
Ross, D.M.1
Branford, S.2
Seymour, J.F.3
Schwarer, A.P.4
Arthur, C.5
Bartley, P.A.6
-
59
-
-
84873084099
-
Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing
-
Eyal E, Tohami T, Amir A, Cesarkas K, Jacob-Hirsch J, Volchek Y, et al. Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing. Br J Haematol 2013;160:477-86
-
(2013)
Br J Haematol
, vol.160
, pp. 477-486
-
-
Eyal, E.1
Tohami, T.2
Amir, A.3
Cesarkas, K.4
Jacob-Hirsch, J.5
Volchek, Y.6
-
60
-
-
84887062699
-
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCRABL kinase domain
-
Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCRABL kinase domain. Blood 2013;122:1634-48
-
(2013)
Blood
, vol.122
, pp. 1634-1648
-
-
Soverini, S.1
De Benedittis, C.2
Machova Polakova, K.3
Brouckova, A.4
Horner, D.5
Iacono, M.6
-
61
-
-
84867250391
-
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
-
Tang M, Foo J, Gonen M, Guilhot J, Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica 2012;97:1553-61
-
(2012)
Haematologica
, vol.97
, pp. 1553-61
-
-
Tang, M.1
Foo, J.2
Gonen, M.3
Guilhot, J.4
Mahon, F.X.5
Michor, F.6
-
62
-
-
84055179140
-
Chronic myeloid leukemia stem cells in the era of targeted therapies: Resistance, persistence and long-term dormancy
-
Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011;2:713-27
-
(2011)
Oncotarget
, vol.2
, pp. 713-27
-
-
Chomel, J.C.1
Turhan, A.G.2
-
63
-
-
79751525883
-
Do we have to kill the last CML cell?
-
Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? Leukemia 2011;25:193-200
-
(2011)
Leukemia
, vol.25
, pp. 193-200
-
-
Ross, D.M.1
Hughes, T.P.2
Melo, J.V.3
-
64
-
-
77950496740
-
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia
-
Burchert A, Muller MC, Kostrewa P, Erben P, Bostel T, Liebler S, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-35
-
(2010)
J Clin Oncol
, vol.28
, pp. 1429-1435
-
-
Burchert, A.1
Muller, M.C.2
Kostrewa, P.3
Erben, P.4
Bostel, T.5
Liebler, S.6
-
65
-
-
81555214617
-
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
-
Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011;118:5565-72
-
(2011)
Blood
, vol.118
, pp. 5565-5572
-
-
Chu, S.1
McDonald, T.2
Lin, A.3
Chakraborty, S.4
Huang, Q.5
Snyder, D.S.6
-
66
-
-
11144354274
-
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
-
Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8
-
(2004)
Blood
, vol.103
, pp. 2873-2878
-
-
Kantarjian, H.1
Talpaz, M.2
O'Brien, S.3
Garcia-Manero, G.4
Verstovsek, S.5
Giles, F.6
-
67
-
-
49149111543
-
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
-
de Lavallade H, Apperley JF,Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63
-
(2008)
J Clin Oncol
, vol.26
, pp. 3358-3363
-
-
De Lavallade, H.1
Apperley, J.F.2
Khorashad, J.S.3
Milojkovic, D.4
Reid, A.G.5
Bua, M.6
-
68
-
-
70350442594
-
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses
-
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-9
-
(2009)
J Clin Oncol
, vol.27
, pp. 4754-4759
-
-
Cortes, J.E.1
Kantarjian, H.M.2
Goldberg, S.L.3
Powell, B.L.4
Giles, F.J.5
Wetzler, M.6
-
69
-
-
84892730457
-
ENEST1st: Nilotinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): A European and EUTOS clinical initiative for standardization of molecular response
-
(abstr 0188)
-
Hochhaus A, Rosti G, le Coutre PD, Ossenkoppele G, Griskevicius L, Rea D, et al. ENEST1st: nilotinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): A European and EUTOS clinical initiative for standardization of molecular response. Haematologica 2012;97(s1):74 (abstr 0188)
-
(2012)
Haematologica
, vol.97
, Issue.1
, pp. 74
-
-
Hochhaus, A.1
Rosti, G.2
Le Coutre, P.D.3
Ossenkoppele, G.4
Griskevicius, L.5
Rea, D.6
-
70
-
-
84861662424
-
Early CP CML, nilotinib 400 mg twice daily frontline: Beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party trial)
-
(abstr 2756)
-
Gugliotta G, Castagnetti F, Breccia M, Levato L, Capucci A, Tiribelli M, et al. Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party trial). Blood 2011;116 (abstr 2756)
-
(2011)
Blood
, pp. 116
-
-
Gugliotta, G.1
Castagnetti, F.2
Breccia, M.3
Levato, L.4
Capucci, A.5
Tiribelli, M.6
-
71
-
-
84877261008
-
Five-year results of nilotinib 400 mg BID in early chronic phase chronic myeloid leukemia (CML): High rate of deep molecular response-update of the GIMEMA CML WP trial CML0307
-
(abstr 3784)
-
Rosti G, Gugliotta G, Castagnetti F, Breccia M, Levato L, Rege- Cambrin G, et al. Five-year results of nilotinib 400 mg BID in early chronic phase chronic myeloid leukemia (CML): high rate of deep molecular response-update of the GIMEMA CML WP trial CML0307. Blood 2012;120 (abstr 3784)
-
(2012)
Blood
, pp. 120
-
-
Rosti, G.1
Gugliotta, G.2
Castagnetti, F.3
Breccia, M.4
Levato, L.5
Rege- Cambrin, G.6
-
72
-
-
75749090051
-
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
-
Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7
-
(2010)
J Clin Oncol
, vol.28
, pp. 392-397
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
Jabbour, E.4
Konopleva, M.5
Ferrajoli, A.6
-
73
-
-
84892761544
-
Pegylated interferon - A 2a in combination to nilotinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemiaprovides high rates of MR4.5. Prelim nary results of a phase II study
-
abstr 166
-
Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, et al. Pegylated interferon-a 2a in combination to nilotinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemiaprovides high rates of MR4.5. Prelim nary results of a phase II study. Blood 2012;120 (suppl; abstr 166)
-
(2012)
Blood
, Issue.SUPPL.
, pp. 120
-
-
Nicolini, F.E.1
Etienne, G.2
Dubruille, V.3
Roy, L.4
Huguet, F.5
Legros, L.6
-
74
-
-
84868552615
-
A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia
-
Radich JP, Kopecky KJ, Applebaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood 2012;120:3898-905
-
(2012)
Blood
, vol.120
, pp. 3898-3905
-
-
Radich, J.P.1
Kopecky, K.J.2
Applebaum, F.R.3
Kamel-Reid, S.4
Stock, W.5
Malnassy, G.6
-
75
-
-
75749129911
-
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
-
Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
-
(2010)
J Clin Oncol
, vol.28
, pp. 398-404
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
Jabbour, E.4
Ravandi, F.5
Koller, C.6
-
76
-
-
84866175467
-
Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: Results from the BELA trial
-
Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicus L, et al. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-92
-
(2012)
J Clin Oncol
, vol.30
, pp. 3486-3492
-
-
Cortes, J.E.1
Kim, D.W.2
Kantarjian, H.M.3
Brummendorf, T.H.4
Dyagil, I.5
Griskevicus, L.6
-
77
-
-
35948937212
-
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinibinduced complete cytogenetic response
-
Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinibinduced complete cytogenetic response. Clin Cancer Res 2007; 13:6136-43
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6136-6143
-
-
Press, R.D.1
Galderisi, C.2
Yang, R.3
Rempfer, C.4
Willis, S.G.5
Mauro, M.J.6
-
78
-
-
84878168513
-
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
-
Lee S, Choi SY, Bang J, Kim S, Jang E, Byeun J, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol 2013;88: 449-54
-
(2013)
Am J Hematol
, vol.88
, pp. 449-454
-
-
Lee, S.1
Choi, S.Y.2
Bang, J.3
Kim, S.4
Jang, E.5
Byeun, J.6
-
79
-
-
84888218224
-
Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib-an updated result of the Keio STIM study
-
(abstr 2788)
-
Matsuki E, Ono Y, Tonegawa K, Sakurai M, Kunimoto H, Ishizawa J, et al. Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib-an updated result of the Keio STIM study. Blood 2012;120 (abstr 2788)
-
(2012)
Blood
, pp. 120
-
-
Matsuki, E.1
Ono, Y.2
Tonegawa, K.3
Sakurai, M.4
Kunimoto, H.5
Ishizawa, J.6
-
80
-
-
84862136806
-
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
-
Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012;97:903-6
-
(2012)
Haematologica
, vol.97
, pp. 903-906
-
-
Takahashi, N.1
Kyo, T.2
Maeda, Y.3
Sugihara, T.4
Usuki, K.5
Kawaguchi, T.6
|